183 related articles for article (PubMed ID: 26382274)
1. D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Zheng R; Xie B; Wang C; Yu B; Xu J; Tan H
Ann Hematol; 2016 Jan; 95(1):157-159. PubMed ID: 26382274
[No Abstract] [Full Text] [Related]
2. [Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Jing Y; Zhu CY; Zhang Q; Niu JH; Yang H; Liu SY; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Oct; 22(5):1245-50. PubMed ID: 25338566
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in MDS-EB and AML-MRC].
Liu J; Jia JS; Gong LZ; Lu SY; Zhu HH; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):734-738. PubMed ID: 30369183
[No Abstract] [Full Text] [Related]
4. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Li J; Chen Y; Zhu Y; Zhou J; Xu Y; Li Y; Yu K; Pan L; Wang J; Ding J; Gu J; Zhou S; Shi J; Hong M; Xu J; Pan L; Duan L; Zhang R; Zhang S; Zhu H; Lu H; Liu P; Qiu H; Wu H; Qian S
Oncotarget; 2015 Mar; 6(8):6448-58. PubMed ID: 25749041
[TBL] [Abstract][Full Text] [Related]
6. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
7. Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.
Zhang J; Sun Y; Zhang X; Long B; Lu Y; Li X
Transplant Proc; 2018; 50(1):246-249. PubMed ID: 29407318
[TBL] [Abstract][Full Text] [Related]
8. [Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Zhu BG; Qian SX; Hong M; Lu H; Wu HX; Zhang SJ; Qiu HX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):760-4. PubMed ID: 19549403
[TBL] [Abstract][Full Text] [Related]
9. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
[TBL] [Abstract][Full Text] [Related]
10. Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation.
Murayama T; Imoto S; Gomyo H; Mizuno I; Kajimoto K; Sugimoto T; Tobinai K; Koizumi T
Hematology; 2001; 6(6):381-5. PubMed ID: 27405694
[TBL] [Abstract][Full Text] [Related]
11. [Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Sun Y; Xu Y; Wu D; Shen H; Yang Z; Qiu H; Chen S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):1025-30. PubMed ID: 26759106
[TBL] [Abstract][Full Text] [Related]
12. Decitabine+ CAG +DLI in relapsed acute myeloid leukemia after allogeneic stem cell transplantation.
Wang B; Jin X; Wang Q; Jing Y
J BUON; 2016; 21(1):280-1. PubMed ID: 27061561
[No Abstract] [Full Text] [Related]
13. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
Wang Y; Li W; Chen S; Qiu H; Sun A; Wu D
Leuk Res; 2011 May; 35(5):604-7. PubMed ID: 21130493
[TBL] [Abstract][Full Text] [Related]
15. Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia.
Huang J; Zhao H; Hong M; Zhu H; Zhu Y; Lian Y; Li S; Li J; Qian S
BMC Cancer; 2018 Dec; 18(1):1269. PubMed ID: 30567513
[TBL] [Abstract][Full Text] [Related]
16. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
Li WY; Wang Y; Chen SN; Qiu HY; Fu ZZ; Wu DP; Sun AN
Leuk Lymphoma; 2018 Jul; 59(7):1652-1658. PubMed ID: 29043875
[TBL] [Abstract][Full Text] [Related]
17. [Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
Yamato H; Yamada K; Koike T; Yoshida M; Tsunogake S; Aoyagi M; Nakamura Y; Watanabe K; Saito K; Enokihara H
Rinsho Ketsueki; 1995 Feb; 36(2):128-33. PubMed ID: 7536277
[TBL] [Abstract][Full Text] [Related]
18. Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
Zhang X; Li Y; Zhang Y; Chen X; Zhang C; Gao L; Kong P; Liu Y; Wen Q; Zeng Y; Wang Q; Su Y; Wang C; Wang S; Yuan Z; Gao L
Leuk Res; 2013 Jun; 37(6):657-64. PubMed ID: 23537708
[TBL] [Abstract][Full Text] [Related]
19. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Wang M; Han HH; Guo R; Liu YF; Jiang ZX; Sun H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1482-1486. PubMed ID: 29070129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
